Market Place
Sourcing Support
Biogen inks $850M deal with TJ for China rights antibody
21 Apr 2026 //
FIERCE BIOTECH
MHRA Approves High-Dose SPINRAZA For Spinal Muscular Atrophy
14 Apr 2026 //
PHARMIWEB
With Trial Looming, Biogen And Investors Settle Aduhelm Claims
08 Apr 2026 //
FIERCE PHARMA
Biogen Links Up With Alloy Platform To Boost ASO Drug Development
07 Apr 2026 //
FIERCE BIOTECH
Biogen Bets on $5.6 Billion buyout of Apellis
31 Mar 2026 //
GLOBENEWSWIRE
Biogen`s Litifilimab Sparkles In Midphase Lupus Trial
30 Mar 2026 //
FIERCE BIOTECH
FDA Approves New High Dose Regimen of SPINRAZA for SMA
30 Mar 2026 //
GLOBENEWSWIRE
Biogen Announces Phase 2 Results for Litifilimab in Lupus in AAD
28 Mar 2026 //
GLOBENEWSWIRE
Alteogen Licenses Hybrozyme To Biogen For Subcutaneous Biologics
25 Mar 2026 //
PR NEWSWIRE
Long-Term LEQEMBI Treatment Persistence Data In Us Revealed
20 Mar 2026 //
PR NEWSWIRE
Long-Term LEQEMBI® Treatment Persistence Data In Us Revealed
20 Mar 2026 //
PR NEWSWIRE
Biogen To Unveil Late-Breaking Litifilimab Ph2 AMETHYST Data
19 Mar 2026 //
GLOBENEWSWIRE
Biogen Reports Salanersen Motor Gains in SMA After Gene Therapy
11 Mar 2026 //
GLOBENEWSWIRE
Biogen Presents New SMA Data at MDA, SMA Europe Conferences
05 Mar 2026 //
GLOBENEWSWIRE
Biogen Announces Board Chair Transition
11 Feb 2026 //
GLOBENEWSWIRE
Biogen`s Alzheimer`s Tau Readout To Raise Further Inquiries
09 Feb 2026 //
BIOSPACE
Biogen`s `Bridge To Growth` Advances Stacked Phase 3 Pipeline
06 Feb 2026 //
BIOSPACE
Leqembi® Sales Reach $20.7B In Q4 2025
06 Feb 2026 //
PR NEWSWIRE BIO
Biogen Bets HD Spinraza Can Outmuscle Roche`s Oral Rival
06 Feb 2026 //
FIERCE PHARMA
Nature Medicine Releases Results Of Pivotal DEVOTE Study
04 Feb 2026 //
GLOBENEWSWIRE
Biogen’s Litifilimab Gains FDA Breakthrough Status for Lupus
28 Jan 2026 //
GLOBENEWSWIRE
Biogen Eyes Alzheimer`s Expansion Post-Leqembi Launch
14 Jan 2026 //
BIOSPACE
Biogen`s High-Dose Spinraza Gets EU Nod for SMA
12 Jan 2026 //
GLOBENEWSWIRE
China Accepts BLA for Subcutaneous LEQEMBI in Early Alzheimer
05 Jan 2026 //
GLOBENEWSWIRE
Samsung Bioepis Launches Byooviz, Biosimilar for Lucentis in EU
02 Jan 2026 //
BUSINESSWIRE
Canada Approves Biogen`s ZURZUVAE for Postpartum Depression
09 Dec 2025 //
PHARMIWEB
Biogen, Stoke Enhance Epilepsy Drug`s Blockbuster Potential
08 Dec 2025 //
BIOSPACE
China Adds LEQEMBI to National Drug Reimbursement List
08 Dec 2025 //
GLOBENEWSWIRE
Biogen Canada`s Zurzuvae Approved in Canada
05 Dec 2025 //
HEALTH CANADA
Stoke, Biogen Unveil Zorevunersen Data Syndrome for Dravet at AES
05 Dec 2025 //
PHARMIWEB
Eisai Reveals Extended Benefits Of LEQEMBI In Early Alzheimer
03 Dec 2025 //
GLOBENEWSWIRE
LEQEMBI Shows Neurotoxic A? Protofibril Impact In Alzheimer`s
02 Dec 2025 //
GLOBENEWSWIRE
Biogen, Stoke Announce Presentations at 2025 AES Annual Meeting
01 Dec 2025 //
GLOBENEWSWIRE
Eisai Files NDA for Subcutaneous LEQEMBI in Early AD in Japan
27 Nov 2025 //
GLOBENEWSWIRE
Eisai Files sBLA with FDA for LEQEMBI in Early Alzheimer Diseases
25 Nov 2025 //
PR NEWSWIRE
Biogen`s Leqembi Rises After Novo GLP-1 Fails In Alzheimer
24 Nov 2025 //
BIOSPACE
Versant Ventures Launches Biogen-Backed Dayra Therapeutics
24 Nov 2025 //
BUSINESSWIRE
Biogen Showcases Lecanemab Data At Alzheimer`s Disease Conference
20 Nov 2025 //
GLOBENEWSWIRE
Biogen Returns To Its Roots With A West Coast Immunology Outpost
18 Nov 2025 //
FIERCE BIOTECH
Stoke, Biogen Publish 2-Year Dravet Data
18 Nov 2025 //
BUSINESSWIRE
Nusinersen High Dose Regimen Gets Positive CHMP Opinion
17 Nov 2025 //
GLOBENEWSWIRE
Biogen Completes Acquisition Of Alcyone Therapeutics
15 Nov 2025 //
GLOBENEWSWIRE
UK Approves Leqembi Iv for Early Alzheimer`s Disease
13 Nov 2025 //
GLOBENEWSWIRE
Biogen Ticks Up Sales Outlook Again As MS Franchise Holds Strong
30 Oct 2025 //
FIERCE PHARMA
Sales of Leqembi Totaled 18 Billion Yen in Third Quarter 2025
30 Oct 2025 //
PR NEWSWIRE
Samsung Bioepis to Launch Byooviz in Europe in January 2026
29 Oct 2025 //
BUSINESSWIRE
Biogen Seeks To Stand Out In Lupus With New Anti-CD40L Data
28 Oct 2025 //
BIOSPACE
Health Canada Authorizes “LEQEMBI” For Early Alzheimer`s Disease
26 Oct 2025 //
GLOBENEWSWIRE
Biogen Licenses Vanqua Bio`s Immune Disorder Drug For $1.06B
25 Oct 2025 //
REUTERS
Biogen To Unveil More Phase 3 Dapirolizumab Pegol Data For Lupus
22 Oct 2025 //
GLOBENEWSWIRE
Leqembi Iqlik Autoinjector Honored in Time`s best Inventions List
14 Oct 2025 //
PR NEWSWIRE
Stoke Therapeutics, Biogen Unveil Zorevunersen Data at Meeting
09 Oct 2025 //
BUSINESSWIRE
Genentech Awarded $124M In Cabilly Patent Dispute With Biogen
06 Oct 2025 //
FIERCE PHARMA
Biogen-Backed Web Series Gets Bill Nye Back In The Lab
30 Sep 2025 //
FIERCE PHARMA
Biogen Shuffles 20 Staff After Ending AAV Work
29 Sep 2025 //
BIOSPACE
China Approves `leqembi` Maintenance Dosing For Early Alzheimer
28 Sep 2025 //
GLOBENEWSWIRE
Biogen Discontinues All Aav Gene Therapy Work
26 Sep 2025 //
FIERCE BIOTECH
Lecanemab Approval For Alzheimer`s Treatment In Australia
24 Sep 2025 //
GLOBENEWSWIRE
FDA Rejects Biogen`s Higher Dose For Genetic Disorder Drug
24 Sep 2025 //
PRESS RELEASE
Biogen Inks $85 M Alcyone Buyout to Acquire Drug Delivery Tech
19 Sep 2025 //
FIERCE BIOTECH
